Try our beta test site
15 studies found for:    Hematologic Malignancies OR lymphoma | IPI-145
Show Display Options
Rank Status Study
1 Enrolling by invitation A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Condition: Hematologic Malignancy
Intervention: Drug: Duvelisib
2 Completed Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Condition: Lymphoma
Intervention: Drug: duvelisib
3 Terminated A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: IPI-145 (duvelisib)
4 Recruiting Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Conditions: Lymphoma;   Relapsed/Refractory T-cell Lymphomas
Interventions: Drug: Romidepsin;   Drug: Bortezomib;   Drug: duvelisib
5 Active, not recruiting Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Placebo;   Drug: Rituximab
6 Active, not recruiting A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
Condition: Indolent Non-Hodgkin Lymphoma
Intervention: Drug: IPI-145 (duvelisib)
7 Active, not recruiting A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Condition: CD20+ Follicular Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Rituximab;   Drug: Obinutuzumab
8 Completed Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Conditions: Lymphoma;   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   T-cell Lymphoma
Interventions: Drug: IPI-145;   Drug: Rituximab;   Drug: Bendamustine
9 Terminated Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Condition: Lymphoma
Interventions: Drug: Duvelisib;   Drug: Rituximab;   Drug: R-CHOP;   Drug: Prednisone
10 Withdrawn A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Drug: Duvelisib;   Drug: Venetoclax
11 Withdrawn A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Interventions: Drug: Duvelisib;   Drug: Placebo;   Drug: Rituximab;   Drug: Bendamustine
12 Recruiting A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
13 Active, not recruiting A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
14 Terminated Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Conditions: Lymphocytic Leukemia, Chronic;   Lymphoma, Small Lymphocytic
Interventions: Drug: IPI-145 (duvelisib);   Drug: Obinutuzumab
15 Withdrawn IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: IPI-145;   Behavioral: Follow-up Visit/Call

Study has passed its completion date and status has not been verified in more than two years.